BEIJING, May 26 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that the Company will participate at the 2010 Shanghai CPhI Exhibition, being held June 2-4, 2010. Sinovac's exhibition booth will be located in Hall E4, No. E4C42. At the exhibition, Sinovac will showcase its commercialized products, including its Healive, Anflu, Panflu and Panflu.1 vaccines.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, remarked, "We are excited to participate in the CPhI Exhibition in Shanghai, where we will feature our high quality products, such as vaccines against hepatitis A and seasonal influenza. As the exhibition attracts a global audience, we look forward to meeting with current and potential new international distribution partners to explore opportunities to further advance our global distribution strategy."
The Shanghai CPhI Exhibition provides Sinovac and other exhibitors/attendees with the opportunity to gain a better understanding of the global pharmaceutical industry. In 2009, a total of 1,651 exhibitors attended the event, including 127 overseas companies from 16 countries and regions. In addition to the exhibition booths, CPhI also hosted 54 high level conferences and seminars during the event, providing exhibitors and attendees with the opportunity to further communicate and exchange the latest information in the pharmaceutical industry.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.
About CPhI Worldwide
CPhI Worldwide was launched in 1990 as an international convention on pharmaceutical ingredients and intermediates. This inaugural CPhI attracted 250 visitors for the 16 exhibitors. Today this has grown to an unrivalled 24,000 industry professionals visiting some 1,500 exhibiting companies from over 125 countries. CPhI is the leading exhibition on pharmaceutical ingredients and allied industries. Each year the exhibition grows larger with exhibitors and visitors conducting significant levels of business at CPhI. Two sister events, ICSE and P-MEC now run alongside CPhI, a tripartite of events that is considered the must attend event for any individual or organisation within the pharmaceutical manufacturing community. In 2001 CPhI was launched in China. ICSE China was launched in 2005 and P-MEC China in 2006.
For more information, please contact:
Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media:
Jason Rando
The Ruth Group
Tel: +1-646-536-7025
Email: jrando@theruthgroup.com
